Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
VBIV 
VBI Vaccines Inc (VBIV)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/08/2024: VBIV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.99% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/08/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.87M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 17329914 | Beta 2.17 | 52 Weeks Range 0.02 - 1.31 | Updated Date 08/14/2024 |
52 Weeks Range 0.02 - 1.31 | Updated Date 08/14/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.54 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2024-08-12 | When Before Market | Estimate -0.32 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -968.04% |
Management Effectiveness
Return on Assets (TTM) -29.15% | Return on Equity (TTM) -419.59% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 38905762 | Price to Sales(TTM) 0.2 |
Enterprise Value 38905762 | Price to Sales(TTM) 0.2 | ||
Enterprise Value to Revenue 4.13 | Enterprise Value to EBITDA -0.69 | Shares Outstanding 28682300 | Shares Floating 26734462 |
Shares Outstanding 28682300 | Shares Floating 26734462 | ||
Percent Insiders 6.77 | Percent Institutions 13.04 |
AI Summary
VBI Vaccines Inc. - A Comprehensive Overview
Company Profile:
History:
Founded in 1988, VBI Vaccines Inc. (Nasdaq: VBIV) is a biopharmaceutical company dedicated to developing innovative vaccines for infectious diseases and immuno-oncology. In 2019, the company acquired SciOne, adding a portfolio of clinical-stage and pre-clinical HIV vaccine candidates to its existing focus on hepatitis B.
Core Business:
- Develops and commercializes prophylactic and therapeutic vaccines for infectious diseases like hepatitis B and HIV.
- Explores vaccines for immuno-oncology applications.
- Operates through two segments: VBI Vaccines and SciOne.
Leadership:
- Jeff Baxter, President & CEO: Extensive experience in the pharmaceutical industry, leading clinical development and commercialization efforts.
- David P. Izzo, CFO: Strong financial expertise, leading corporate finance strategy and operations.
- Dr. Saira Hussain, CMO: Extensive experience in clinical development of vaccines and biologics.
Top Products and Market Share:
- Sci-B-Vac: A therapeutic vaccine for chronic hepatitis B infection. Approved in Taiwan and filed for regulatory approval in the US and Europe.
- Pre-clinical HIV vaccine candidates: Several candidates in development, aiming for a functional cure for HIV.
- Market Share:
- Sci-B-Vac holds a dominant position in the chronic hepatitis B market in Taiwan.
- HIV vaccine market is highly competitive, with VBI's candidates still in development.
Total Addressable Market:
- Hepatitis B: Estimated 296 million chronic hepatitis B cases globally, representing a significant market opportunity.
- HIV: Approximately 38 million people living with HIV worldwide, demonstrating a substantial market potential for a functional cure.
Financial Performance:
- Revenue: Primarily driven by Sci-B-Vac sales in Taiwan. Revenue growth observed in recent years.
- Net Income: Currently reporting net losses due to ongoing research and development investments.
- Profit Margins: Negative, reflecting the company's investment phase.
- Earnings per Share (EPS): Negative due to net losses.
- Cash Flow: Primarily driven by financing activities. Operating cash flow remains negative.
- Balance Sheet: Adequate cash reserves to support ongoing operations.
Dividends and Shareholder Returns:
- No dividend payments currently.
- Shareholder Returns: Negative in recent years due to stock price volatility.
Growth Trajectory:
- Historical Growth: Revenue growth observed in recent years, driven by Sci-B-Vac sales.
- Future Growth: Contingent on successful regulatory approvals and market adoption of Sci-B-Vac in the US and Europe, and success of HIV vaccine candidates.
- Recent Initiatives: Ongoing clinical trials and regulatory filings for Sci-B-Vac and HIV vaccine candidates.
Market Dynamics:
- Hepatitis B vaccine market: Highly competitive, with established players and generic competition.
- HIV vaccine market: Dynamic and evolving, with ongoing research and development efforts from various players.
- VBI's Positioning: Innovative technology platform and promising pipeline, but facing intense competition.
Competitors:
- Hepatitis B: GSK, Merck, Sanofi Pasteur
- HIV: Moderna (MRNA), Johnson & Johnson (JNJ), Pfizer (PFE)
Potential Challenges and Opportunities:
- Challenges: Regulatory hurdles, competition, R&D costs, funding requirements.
- Opportunities: Expanding market access for Sci-B-Vac, success of HIV vaccine candidates, strategic partnerships.
AI-Based Fundamental Rating:
Rating: 6/10
Justification:
- Positives: Innovative product portfolio, promising pipeline, growing revenue.
- Negatives: Lack of profitability, intense competition, reliance on limited products.
Sources:
- VBI Vaccines Inc. Investor Relations: https://ir.vbivaccines.com/
- Yahoo Finance: https://finance.yahoo.com/quote/VBIV/
- SEC Filings: https://www.sec.gov/edgar/search/
Disclaimer:
This information is for educational purposes only and should not be considered investment advice. Please consult with a qualified financial professional before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1995-08-18 | President, CEO & Director Mr. Jeffery R. Baxter FCMA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.vbivaccines.com |
Full time employees 131 | Website https://www.vbivaccines.com | ||
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.